PSMA靶向放射性示踪剂与18F氟环丁氨酸在根治性治疗后前列腺癌生化复发检测中的比较:系统评价与Meta分析
该系统评价与Meta分析比较了PSMA靶向放射性示踪剂与18F氟环丁氨酸PET/CT在PSA<2 ng/mL的生化复发前列腺癌患者中的检出率。汇总分析显示,PSA 1.0-1.9 ng/mL时PSMA检出率80%高于氟环丁氨酸62%(P=0.01);PSA<0.5及0.5-0.9 ng/mL时两者差异无统计学意义。
要点
- PSA 1.0-1.9 ng/mL时PSMA示踪剂检出率80%,高于氟环丁氨酸的62%(P=0.01)。
- PSA<0.5 ng/mL时两者检出率差异无统计学意义(45% vs 37%,P=0.46)。
- PSA 0.5-0.9 ng/mL时两者检出率差异亦无统计学意义(59% vs 48%,P=0.19)。
核心结论
- 在PSA 1.0-1.9 ng/mL的生化复发前列腺癌患者中,PSMA靶向放射性示踪剂的患者水平检出率高于氟环丁氨酸。
研究设计与样本
- 系统评价与Meta分析,遵循PRISMA-DTA指南,检索PubMed和EMBASE数据库2012年至2019年的文献。
- 定量分析纳入6项氟环丁氨酸研究共482例患者(中位年龄67岁,四分位距67-67岁)和38项PSMA研究共3217例患者(中位年龄68岁,四分位距67-70岁)。
- 采用随机效应模型对阳性检查患病率的汇总估计值及95%CI进行分层分析,分层依据为PSA水平。
诊断标准与关键数值
- PSA<0.5 ng/mL时,PSMA汇总检出率45%(95%CI:38%,52%),氟环丁氨酸37%(95%CI:25%,49%),P=0.46。
- PSA 0.5-0.9 ng/mL时,PSMA汇总检出率59%(95%CI:52%,66%),氟环丁氨酸48%(95%CI:34%,61%),P=0.19。
- PSA 1.0-1.9 ng/mL时,PSMA汇总检出率80%(95%CI:75%,85%),氟环丁氨酸62%(95%CI:54%,70%),P=0.01。
- 参考标准阳性:PSMA队列735例中703例(96%),氟环丁氨酸队列256例中247例(97%)。
临床应用与阅片要点
- 对于根治性治疗后PSA 1.0-1.9 ng/mL的生化复发患者,PSMA靶向放射性示踪剂的患者水平检出率高于氟环丁氨酸。
- 对于PSA<0.5 ng/mL及0.5-0.9 ng/mL的生化复发患者,PSMA与氟环丁氨酸的检出率差异无统计学意义。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Background National guidelines endorse fluorine 18 (18F) fluciclovine PET/CT for the detection of prostate cancer (PCa) in men with biochemically recurrent PCa. The comparative performance between fluciclovine and gallium 68 or 18F prostate-specific membrane antigen (PSMA) PET/CT, a newer examination, is unclear. Purpose To compare the detection of biochemical recurrence using fluciclovine versus PSMA-targeted radiotracers in patients with a prostate-specific antigen (PSA) level less than 2 ng/mL. Materials and Methods With use of the Preferred Reporting Items for a Systematic Review and Meta-Analysis of Diagnostic Test Accuracy, or PRISMA-DTA, guidelines, a systematic review of PubMed and EMBASE databases between 2012 and 2019 was performed. Studies of fluciclovine PET/CT or PSMA PET/CT in biochemical recurrence were identified. PSA levels, clinical data, and reference standards were obtained when available. A random-effects model was applied to pooled estimates and 95% confidence intervals (CIs) around the prevalence of a positive examination, stratified according to PSA tier. Results Quantitative analysis included 482 patients (median age, 67 years; interquartile range, 67-67 years) in six fluciclovine studies and 3217 patients (median age, 68 years; interquartile range, 67-70 years) in 38 PSMA studies. Pooled detection rates for PSMA and fluciclovine were 45% (95% CI: 38%, 52%) and 37% (95% CI: 25%, 49%), respectively, for a PSA level less than 0.5 ng/mL (P = .46); 59% (95% CI: 52%, 66%) and 48% (95% CI: 34%, 61%) for a PSA level of 0.5-0.9 ng/mL (P = .19); and 80% (95% CI: 75%, 85%) and 62% (95% CI: 54%, 70%) for a PSA level of 1.0-1.9 ng/mL (P = .01). A reference standard was positive in 703 of 735 patients (96%) in the PSMA cohort and 247of 256 (97%) in the fluciclovine cohort. Conclusion Patient-level detection rates for biochemically recurrent prostate cancer were greater for prostate-specific membrane antigen-targeted radiotracers than fluciclovine for prostate specific antigen levels of 1.0-1.9 ng/mL. © RSNA, 2020 Online supplemental material is available for this article.
引用
- Tan N, Oyoyo U, Bavadian N, et al. PSMA-targeted Radiotracers versus 18F Fluciclovine for the Detection of Prostate Cancer Biochemical Recurrence after Definitive Therapy: A Systematic Review and Meta-Analysis. Radiology. 2020. PMID: 32396045. doi:10.1148/radiol.2020191689
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。